ArticleBlood2009
Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00331968, which is not on this map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Keratinocytes as active regulators of cutaneous and mucosal immunity: a systematic review across inflammatory epithelial disorders.Frontiers in immunology · 2025Pooled it
- The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.International journal of molecular sciences · 2019Pooled it
- Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.Clinical oral investigations · 2011Guideline
- Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD.Blood advances · 2019Trial
- Trial
- Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.Journal of immunology (Baltimore, Md. : 1950) · 2016Trial
- Lichenoid graft-versus-host disease shows a high interferon score, with IFNAR1 inhibition preventing skin inflammation.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Exhausted-like effector CD8 T cells mediate immune-stromal interactions at mucosal Chronic Graft-versus-Host Disease onset.bioRxiv : the preprint server for biology · 2025Article
- Addressing Knowledge Gaps in the Early Detection of Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2025Article
- Article
- Oral Chronic Graft-Versus-Host Disease: Pathogenesis, Diagnosis, Current Treatment, and Emerging Therapies.International journal of molecular sciences · 2024Review
- Article
- Perspectives on oral chronic graft-versus-host disease from immunobiology to morbid diagnoses.Frontiers in immunology · 2023Review
- Observational
- Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD.Blood cancer journal · 2021Article
- Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease.Frontiers in immunology · 2020Review
- Oral Complications of Chronic Graft-Versus-Host Disease.Journal of the National Cancer Institute. Monographs · 2019Review
- The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease.Frontiers in immunology · 2019Review
- The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.British journal of cancer · 2018Article
- Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study.Oral diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Although chronic graft-versus-host disease (cGVHD) is a major long-term complication of allogeneic hematopoietic stem cell transplantation, little is known of its pathogenesis. We have systematically examined oral mucosa among cGVHD patients and determined that the clinical severity of oral cGVHD was correlated with apoptotic epithelial cells, often found adjacent to infiltrating effector-memory T cells expressing markers of cytotoxicity and type I cytokine polarization. Accumulation of T-bet(+) T-cell effectors was associated with both increased proliferation and the expression of the type I chemokine receptor CXCR3. Concurrently, in both infiltrating cells and keratinocytes, we observed increased expression of the CXCR3 ligand MIG (CXCL9) and interleukin-15 (IL-15), type I interferon (IFN)-inducible factors that support the migration, type I differentiation, and expansion of alloreactive effectors. In severely affected mucosa, we observed high levels of MxA, a protein specifically induced by type I IFN, and signal transducer and activator of transcription 1 (STAT1) phosphorylation, a critical step in the IFN-signaling pathway, along with increased numbers of plasmacytoid dendritic cells. These data challenge the current paradigm of cGVHD as a type II cytokine-driven disorder and support the model that oral cGVHD results from type I IFN-driven immigration, proliferation, and differentiation of T-bet(+) type I T effectors. The clinical trials are registered at http://www.clinicaltrials.gov as NCT00331968.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.